SLC5A2 and polycystic ovary syndrome: Moreover, our study shows that inhibition of SGLT2 with EMPA decreases fat mass, plasma leptin, and BP but fails to improve IR, HbA1c, or albuminuria in an animal experimental model of PCOS.